ripretinib 50 MG Oral Tablet

RxCUI: 2369397
RxNorm name: ripretinib 50 MG Oral Tablet
Display name: ripretinib 50 MG Oral Tablet
Full name: ripretinib 50 MG Oral Tablet
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:39:10

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
QINLOCK	RIPRETINIB	Deciphera Pharmaceuticals, LLC	9f18e462-03dd-4296-a02a-a0577e3ee78d	2025-05-12	Warnings, Adverse reactions	Exact identifier rxcui: 2369397

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
9f18e462-03dd-4296-a02a-a0577e3ee78d	ripretinib 50 MG Oral Tablet [PSN] · ripretinib 50 MG Oral Tablet [SCD]	2	9	These highlights do not include all the information needed to use QINLOCK safely and effectively. See full prescribing information for QINLOCK. QINLOCK ® (ripretinib) tablets, for oral use Initial U.S. Approval: 2020	20250512